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                                         INTRODUCTION
Idiopathic inflammatory bowel disease (IBD) comprises conditions 
characterized by a tendency for chronic or relapsing immune activation 
and inflammation  within  the  gastrointestinal  tract.  Crohn's  disease  and 
ulcerative colitis are the two major forms of idiopathic IBD. They share 
many  clinical  and  epidemiologic  characteristics,  suggesting  that 
underlying  causation  may  be  similar.  Indeed,  more  than  occasionally 
Crohn's disease cannot be distinguished from ulcerative colitis on clinical 
grounds,  yet  the  two  diseases  are  distinct  syndromes  with  divergent 
treatment  and  prognosis.IBD  manifest  mainly  with  intestinal 
manifestations as well as with extraintestinal manifestations. The various 
extraintestinal  manifestations  include  musculoskeletal,  mucocutaneous, 
hepatobiliary,  hematologic  &  vascular,  ocular,  renal&  genitourinary 
manifestations and others.  Among these , hepatobiliary manifestation in 
the form of fatty liver and musculoskeletal manifestation in the form of 
pauciarthralgia are the most commonly seen. 
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REVIEW OF LITERATURE
HISTORICAL   REVIEW
                Although the eponym, “Crohn's disease” has gained general 
acceptance in recent decades, it was Morgagni who provided a description 
of intestinal inflammation characteristic of Crohn's disease in 17611. Only 
after the identification of the tubercle bacillus by Koch in 1882, was it 
possible  to  describe persons with ileocecal  disease similar  to  intestinal 
tuberculosis  but  lacking  the  organism.  Such  reports  were  provided  by 
Fenwick  (1889)1,  Dalziel  (1913)2,  Weiner  (1914),  Moschcowitz  and 
Wilensky (1923 and 1927), and Goldfarb and Suissman (1931)3. In 1932, 
the  landmark  publication  of  Crohn  and  his  colleagues  Ginzburg  and 
Oppenheimer called attention to “terminal ileitis” as a distinct entity and 
chronic disease4.  
              Dr. Samuel Wilks is credited with being the first to describe  
Ulcerative  Colitis  disorder  in  1859  when  he  described  this  entity  as 
“idiopathic  colitis”  and  recognized  it  as  distinct  from  the  then  more 
common bacillary dysentery5. He also reported the pathologic finding of 
dilated and thinned colon with severe universal inflammation in a patient 
with this condition6. In 1909, Hawkins described the chronic and relapsing 
nature of the disease course, and the “stealthy hemorrhage” onset of distal 
disease in which bleeding often occurred in the presence of constipation7. 
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                             DEFINITION
Crohn's  disease  (CD)  is  a  condition  of  chronic  inflammation 
potentially involving any location of the alimentary tract from mouth to 
anus, but with a propensity for the distal small bowel and proximal large 
bowel. Ulcerative colitis (UC) is a chronic inflammatory disorder of the 
gastrointestinal tract that affects the large bowel and is a major disorder 
under the broad group of inflammatory bowel diseases .
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GENERAL ASPECTS OF IBD
EPIDEMIOLOGY 
CROHN’S DISEASE (CD)
A recent systematic review noted an incidence in North America 
ranging from 3.1  to  14.6  per  100,000 person-years8. It  is  considerably 
lower among the non-white population. Female-to-male ratio is between 
unity  and  1.2:1.Crohn's  disease  is  diagnosed  most  frequently  among 
persons  aged  15  to  30  years,  the  median  age  of  diagnosis  to  be 
approximately 30 years9,10. Studies have shown a smaller second peak in 
incidence later in life, generally in the 7th decade11.
ULCERATIVE COLITIS(UC) 
 In North America, the incidence rates range from 6.0 to 14.3 cases 
per 100,000 person-years and the prevalence ranges from 37 to 246 cases 
per 100,000 persons12. In Europe, the incidence rates range from 1.5 to 
20.3 cases per 100,000 person-years and the prevalence ranges from 21 to 
243 cases per 100,000 persons12. These time trends are in contrast with 
those of Crohn's disease, which has shown an increase in incidence across 
geographic regions. The prevalence of UC in India has been reported to be 
substantially lower than that among Europeans13. South Asian immigrants 
in England are more likely to have UC than are European natives13-15. UC 
may present at all ages, although diagnosis before the age of 5 years or 
after 75 years is uncommon. The peak incidence of UC occurs in the 2nd 
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and 3rd decades of life. Studies have reported a second, smaller peak in 
the elderly, between the ages of 60 and 70 years. This second peak is less 
pronounced than that for Crohn's disease. Most studies have not shown 
any gender difference in the occurrence of UC and a male-to-female ratio 
of nearly 1:1 applies to all age groups.
II. AETIOLOGY
A .IMMUNOLOGICAL FACTORS
CROHN’S DISEASE
IBD  represents  a  state  of  sustained  immune  response.  Many 
infectious  agents  have  been  proposed  as  the  cause  of  Crohn's  disease 
including  Chlamydia,  Listeria  monocytogenes,  cell  wall–deficient 
Pseudomonas  species,  reovirus,  Paramyxovirus  (measles  virus)  and 
Mycobacterium  paratuberculosis.  Non-pathogenic  commensal  enteric 
flora  are  sufficient  to  induce  a  chronic  inflammatory  response.  The 
presence  of  low-level  physiologic  inflammation  within  the  healthy 
intestinal  mucosa  represents  a  state  of  preparedness  to  deal  with 
potentially  harmful  agents,  a  more  vigorous  response  would  not  be 
appropriate if directed toward the innocuous commensal flora of the gut. 
Inflammation is kept in check through immune tolerance by subsets of 
CD4+  helper  T  cells  that  are  generated  in  the  intestinal  mucosa  and 
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secrete the down-regulatory cytokines, transforming growth factor (TGF)-
β1 and interleukin (IL)-10. Two specific T cell populations—T regulatory 
1  (Tr1)  and  T  helper  3  (Th3)  cells—appear  to  have  similar  roles  in 
maintaining  mucosal  tolerance  in  the  intestine16.When  an  antigenic 
challenge occurs, or when tolerance is broken, the immune response may 
be skewed toward cell-mediated immunity or toward humoral immunity 
with the production of  characteristic  cytokine profiles  by CD4+ T cell 
populations. Th1 cells are characterized by their production of a typical 
cytokine profile of  IL-2 and interferon (IFN)-γ. In Crohn's disease, CD4+ 
T cells  have  a  Th1  cytokine  profile,  whereas  in  ulcerative  colitis,  the 
cytokine  profile  is  that  of  a  Th2  response,  although  lacking  in  IL-4 
expression17.Sustained  nature  of  the  inflammation  is  the  result  of 
abnormal  barrier function. An intriguing observation in humans is that 
bone marrow transplantation may cure Crohn's disease18, whereas small 
bowel  transplantation  may  not19.  This  observation  suggests  that 
immunologic defects, rather than defects intrinsic to the bowel, may be 
paramount.  Poor  intestinal  barrier  function  ,  sustained  exaggerated 
inflammatory reaction from an ineffective immune response, programmed 
over  responsiveness  to  a  persistent  stimulus  and   defective  apoptosis20 
accounts for the sustained nature of inflammation in IBD. On activation, 
macrophages  further  shape  and  amplify  the  immune  response  by 
producing  IL-2  and  the  pro-inflammatory  cytokines  IL-1  and  TNF.  In 
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addition to   being essential to the formation of granuloma, TNF causes 
neutrophil  activation  and  along  with  IFN γ  induces  the  expression  of 
MHC class  II on intestinal epithelial cells.
ULCERATIVE COLITIS
The prevailing theory of the pathogenesis of UC emphasizes the 
role of enteric immune response. The physiologic state of the intestine is 
one  of  constant  low-grade  inflammation  in  response  to  environmental 
stimuli such as bacterial products or endogenous factors. Breaches in this 
well-regulated mucosal immune system lead to the chronic uncontrolled 
mucosal  inflammation  observed  in  UC.  In  this  regard,  immunologic 
mechanisms in the pathogenesis of UC involve both humoral and cell-
mediated responses.
(a)Humoral Immunity
Histologic examination of the inflamed colon indicates a marked 
increase  in  the  number  of  plasma  cells.  This  increase  is  not  uniform 
among cells producing different classes of immunoglobulins. The largest 
proportional  increase  occurs  in  IgG  synthesis,  which  has  the  highest 
pathogenic  potential  among  antibody  classes.  The  increase  in  IgG 
synthesis in UC is most pronounced in the IgG1 and IgG3 subclasses, in 
contrast  to  Crohn's  disease,  in  which the increase  in  IgG2 synthesis  is 
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more prominent. [21,22] This disparity in the local  IgG subclass response 
likely reflects differences in antigenic stimuli or host immunoregulatory 
responses between the two groups of  IBD patients.  The increased IgG 
synthesis in IBD may represent polyclonal stimulation; however, patients 
with UC frequently have circulating antibodies to dietary, bacterial, and 
self-antigens that are mostly of the IgG isotype, usually the IgG1 subclass. 
Many of these antibodies are thought to be epiphenomena because the 
serum  antibody  titers  do  not  correlate  with  clinical  parameters. 
Nevertheless, the known cross-reaction between enterobacterial antigens 
and colonic epithelial epitopes may be an important triggering event, even 
though, later in the course of the disease, the serum antibody titer to either 
the bacterial or the colonic antigen may be unimportant. The concept that 
UC is an autoimmune disease is supported by its  increased association 
with other autoimmune disorders, including thyroid disease, diabetes, and 
pernicious anaemia23. The best characterized intestinal autoantigen is an 
epithelial antigen of 40-kd size found in normal colonic epithelium.24 This 
autoantigen  is  recognized  by  IgG  eluted  from  the  inflamed  colonic 
mucosa  of  patients  with  UC  and  is  a  component  of  the  tropomyosin 
family of cytoskeletal proteins.[25] This autoantibody has the potential to 
activate  complement  in  vivo,  but  direct  evidence  of  antibody-induced 
cytotoxicity has not been observed. The antibody response to this 40-kd 
protein appears to be unique to UC and is not found in Crohn's disease or 
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other inflammatory conditions. This autoantigen shares an epitope with 
antigens found in the skin, bile duct, eyes and joints, [26] [27] sites frequently 
involved  in  the  extraintestinal  manifestations  of  UC.  The  precise 
pathogenic  significance  of  this  autoantibody in UC remains  unclear  at 
present.  An  autoantibody  that  has  received  significant  attention  is 
pANCA.[28] This autoantibody is present in 60% to 85% of patients with 
UC. [29]  [30] It is synthesized within the lamina propria and is of the IgG1 
subclass. The antigen to which the pANCA is directed has not yet been 
determined with certainty, and a variety of putative antigens have been 
proposed,  including nuclear  histone and nonhistone proteins.  The most 
recent  evidence  suggests  that  the  antigen  is  a  50-kd  nuclear  envelope 
protein that is specific to myeloid cells31. The level of pANCA titer does 
not correlate with disease activity but may decline in patients with long-
standing remission or in patients who have had colectomy for at least 10 
years. Studies have suggested that pANCA may be associated with a more 
aggressive disease course[32] and the development of pouchitis following 
ileal pouch-anal anastomosis (IPAA) in patients with UC.[33]
(b)Cellular Immunity
Immune dysregulation in UC also involves cell-mediated immunity. 
The  mucosal  T  cells  can  be  divided  into  two  anatomically  different 
groups:  lamina  propria  lymphocytes  and  intraepithelial  lymphocytes 
(IELs). Immune cells within the lamina propria consist of a mixture of cell 
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types, including T cells,  B cells,  macrophages, and dendritic cells.  The 
most  common  immune  cells  are  IgA-secreting  plasma  cells.  Lamina 
propria  lymphocytes  express  surface  adhesion  molecules,  α4β7,  that 
provide a homing signal for peripheral immune cells to the mucosal sites.
[34] Most investigators have found a similar distribution of T cell subsets 
(CD4+,  CD8+ within the lamina propria  in patients  with UC compared 
with that in controls).[35] Lamina propria lymphocytes have been reported 
to  be  cytotoxic  to  autologous  colonic  epithelial  cells,  but  the  exact 
mechanisms  are  unknown and  the  results  have  not  been  confirmed.[36] 
Helper  function  mainly  has  involved  the  effects  of  T  cells  on 
immunoglobulin production by B cells, but the results have been varied 
and do not provide firm evidence for an underlying immune abnormality 
in  UC.  Studies  using  nonspecific  mitogens  have  found  diminished 
suppressor  activity  during  active  disease  only,  but  an  antigen-induced 
suppressor assay has shown that patients with UC in remission exhibited 
suppressor  defects  to  a  range  of  mycobacterial  and  enterobacterial 
antigens.[37] This  phenomenon  of  antigen-induced  suppression  was 
predominantly CD8+ cell dependent and correlated with a poor response to 
skin testing with purified protein derivative; these defects were limited to 
the peripheral blood and not lamina propria lymphocytes. In patients with 
UC, the absolute number of IELs is normal or reduced. Most of these cells 
are CD8+ cells, and the function of IELs has not been well characterized. 
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It has been suggested that they are cytotoxic and also may be active in 
suppressing local immune response. In patients with UC, the proportion of 
IELs using the γδ T cell receptor may increase.[38] However, the function 
and significance of γδ T cells are unknown. Regardless of their functional 
status, mucosal T cells within the lamina propria and epithelium as well as 
peripheral blood T cells display a variety of activation markers, suggesting 
an  activated  memory  phenotype.[39] Studies  have  suggested  that  T cell 
receptor repertoire is altered in active IBD.[40] Studies have also shown 
restricted Vβ usage, but there is no distinct pattern when compared with T 
cells from healthy lamina propria. Although T cell mediated immunity has 
attracted the most attention in the pathogenesis of UC, nonspecific cellular 
immunity  also  is  altered.  In  patients  with  active  disease,  there  is  an 
overproduction of circulating monocytes as well as mucosal macrophages.
[41] The inflamed mucosa of patients with UC also exhibits infiltration of 
substantial numbers of granulocytes.
                  Activation of macrophages, lymphocytes and colonic epithelial 
cells  leads  to  the  release  of  a  variety  of  cytokines  and mediators  that 
further amplify the immune and inflammatory response of UC and result 
in tissue damage. Based on the cytokines they produce, CD4+ T cells have 
been divided into two major immune phenotypes: T helper 1 (Th1) and T 
helper  2  (Th2).  The  Th1  response  is  characterized  by  cell-mediated 
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immunity and is associated with the production of interleukin (IL)-2 and 
interferon (IFN)-γ. The differentiation of T cells along a Th1 pathway is 
stimulated  by  IL-12  generated  in  response  to  exposure  to  infectious 
agents. The Th2 response is characterized by the production of cytokines 
IL-4, IL-5 and IL-10, which amplify the humoral immune response. Th1 
and Th2 subsets reciprocally down-regulate each other through cytokine 
production.[42] Both Th1 and Th2 pathways can be regulated by unique 
regulatory T cells (Th3, T regulatory 1) subsets that produce IL-10 and 
transforming  growth  factor-β  and  down-regulate  inflammation.[43] 
Macrophages in the inflamed colon in patients with active UC synthesize 
IL-1β, TNF and IL-6, whereas lamina propria T cells probably produce 
IL-2 and IFN-γ.  This immune response can be up-regulated further  by 
presentation of antigen to CD4+ lymphocytes by colonic epithelial cells 
that express HLA class II antigens.[44] Release of these cytokines also may 
lead to other abnormalities seen in UC, such as increased epithelial cell 
permeability  and  collagen  synthesis.  Alteration  of  endothelium  by  a 
variety of cytokines may result in local ischemia. Increased expression of 
endothelial  adhesion molecules in  response to  inflammatory mediators, 
recruits circulating granulocytes and monocytes to the inflamed tissues, 
thus further  perpetuating the inflammatory response.  Elevated cytokine 
levels within the mucosa also stimulate the release of metalloproteinase 
from  fibroblasts  with  subsequent  matrix  degradation.  Mucosal 
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concentrations  of  many  mediators  have  been  shown  to  be  elevated  in 
patients  with  active  UC,  including leukotrienes,  thromboxane,  platelet-
activating factor,  nitric oxide and reactive oxygen metabolites.[45] These 
mediators,  which  are  mostly  released  from  active  macrophages  and 
neutrophils, contribute to inflammation and mucosal injury, alter epithelial 
cell  permeability,  and  interfere  with  iron  transport,  thereby  further 
contributing to diarrhea. Diarrhea in UC also is caused by complement 
activation  and  the  release  of  kinins  and  other  inflammatory  mediators 
from mast cells and eosinophils .
B.GENETIC FACTORS
CROHN’S DISEASE
    The  relative  risk  among  first-degree  relatives  is  14  to  15  times 
higher  than  that  of  the  general  population46 especially  in   Eastern 
European (Ashkenazi) Jews. Studies of monozygotic and dizygotic twins 
suggest, genetic composition is a more powerful determinant for Crohn's 
disease  than  for  ulcerative  colitis:  The  concordance  rate  among 
monozygotic twins is as high as 67% for Crohn's disease, but only 13% to 
20% for ulcerative colitis.  Specific IBD genes on chromosome 16 (the 
IBD1  locus)  had  been  confirmed  repeatedly  to  be  linked  to  Crohn's 
disease.  The  IBD1  locus  as  the  NOD2  (nucleotide-binding 
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oligomerization  domain  2)  gene,  also  known  as  CARD15  (caspase-
recruitment domain 15)47,48  are associated with younger onset of disease, 
ileal  location  of  disease,  and  increased  likelihood  of  stricture 
formation.The  OCTN  (organic  cation  transporter)  gene,  chromosome 
5q31  and  DLG5,  located  on  chromosome  10q23,  may  play  a  role  in 
maintaining normal cellular structure49,50,51,52..
ULCERATIVE COLITIS
     About 10% to 20% of patients have at least one other affected family 
member53.Clinical characteristics of familial disease also have shown that 
the onset of disease in a child is noted at a much earlier age than in the 
affected  parent,  but  there  is  a  high  degree  of  concordance  between 
affected  siblings  for  age  of  onset.  Approximately  6%  to  16%  of 
monozygotic twin pairs had concordant UC compared with 0% to 5% of 
dizygotic  twin pairs54,55,56.Linkage studies have suggested that  there  are 
susceptibility genes for UC on chromosomes 2, 3, 6, 7, and 1257,58. The 
IBD2 locus  on  chromosome  12  appears  to  have  the  strongest  linkage 
demonstrated  in  studies  involving  large  numbers  of  families  with 
UC59.C3435T  polymorphism  for  the  human  multidrug  resistance  1 
(MDR1)  gene  to  susceptibility  for  UC60.Association  between  severe 
disease and a rare allele of HLA-DR1 (DRB1*0103) has been reported. In 
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some studies, the HLA-DR3, DQ2 haplotype is associated with extensive 
colitis, especially among women.
C.ENVIRONMENTAL FACTORS
CROHN’S DISEASE
    Breast feeding has been found to be protective for IBD. Occupations 
associated with outdoor physical labour are relatively under-represented 
among Crohn's  patients,  and Crohn's  disease  has  been  associated  with 
higher socio-economic status61.Studies have discerned an increased risk of 
Crohn's disease among women who use oral contraceptives. Non-steroidal 
anti-inflammatory drugs (NSAIDs) have been implicated in exacerbations 
of IBD and as a potential precipitant of new cases. Increased intake of 
refined sugars and a paucity of fresh fruits and vegetables in the diet have 
been  associated  with  the  development  of  Crohn's  disease.  Ulcerative 
colitis     is largely a disease of ex-smokers and non-smokers,  whereas 
Crohn's  disease  is  more  prevalent  among  smokers,  and  smokers  have 
more surgery for their disease and a greater risk of relapse after resection. 
ULCERATIVE COLITIS
      No  specific  infective  organism,  however,  has  been  isolated 
consistently  from patients with UC. It  is  possible that  products of the 
commensal flora promote inflammation in the presence of an impaired 
mucosal  barrier  or  injury to  the mucosa62 and have reduced tolerance 
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toward their own intestinal flora63,64. UC is more common among non-
smokers than among current smokers, with the relative risk of UC in non-
smokers ranging from 2 to 665. This risk of developing UC with smoking 
is particularly high for former smokers, especially within the first 2 years 
of  smoking  cessation.  Smokers  also  appear  to  have  reduced  rates  of 
hospitalization  for  UC  and  reduced  rates  of  pouchitis  following 
colectomy66.  Breast-feeding has been suggested to be protective against 
the development of UC67.Studies show a negative association between 
appendectomy and subsequent development of UC68,69.
D.PSYCHOGENIC FACTORS
      Stress  has  been  shown  to  increase  the  severity  of  colonic 
inflammation.
III. PATHOLOGY
CROHN’S DIEASE
      Focal intestinal inflammation is the hallmark pathologic finding in 
Crohn's disease. The earliest characteristic lesion of Crohn's disease is the 
aphthous  ulcer.  The presence  of  granulomas is  highly  characteristic  of 
Crohn's disease. Lately, it  show localized foci of architectural distortion 
unaccompanied by chronic inflammation. Disease becomes chronic and, 
aphthae may coalesce into larger ulcers with a stellate appearance. The 
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presence of lymphoid aggregates in both the submucosa and external to 
the muscularis propria are a reliable sign of Crohn's disease .Large ulcers, 
sinus tracts,  and strictures are late features of Crohn's disease. Fibrosis 
along with hypertrophy of the muscularis mucosa, may contribute to the 
development of strictures. Fat wrapping is highly characteristic of Crohn's 
disease. Crohn's disease has a predilection for the distal small bowel and 
proximal  large  bowel.  Nearly  one  half  of  all  patients  have  disease 
affecting both ileum and colon. Another one third have disease confined to 
the small bowel, primarily the terminal ileum and in some cases including 
the jejunum as well10.
ULCERATIVE COLITIS
        At time of initial presentation, approximately 45% of patients with 
UC have disease limited to the rectosigmoid, 35% have disease extending 
beyond  the  sigmoid  but  not  involving  the  entire  colon,  and  20%  of 
patients have pancolitis70. The disease typically is most severe distally. In 
contrast to Crohn's disease, continuous and symmetrical involvement is 
the  hallmark  of  UC.  75%  of  patients  with  left-sided  UC  may  have 
appendiceal  inflammation  and  patchy  inflammation  in  the  cecum71, 
resembling the skip pattern characteristic of Crohn's disease.  Epithelial 
regeneration  with  recurrent  attacks  results  in  the  formation  of 
pseudopolyps,  which  is  typical  of  long-standing  UC.  Another 
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characteristic  appearance  of  long  standing  disease  is  atrophic  and 
featureless colonic mucosa, associated with shortening and narrowing of 
the colon. Patients with severe disease may develop acute dilatation of the 
colon.  During  the  healing  phase  of  UC,  the  inflammatory  infiltrate 
subsides and epithelial regeneration takes place. Classic histologic feature 
of chronic quiescent UC is crypt architectural distortion or actual dropout 
of  glands.  Another  characteristic  feature  of  chronic  quiescent  UC  is 
Paneth  cell  metaplasia,  with  the  presence  of  Paneth  cells  beyond  the 
hepatic flexure, where they typically are absent.
IV.CLINICAL FEATURES
CROHN’S DISEASE
          Compared with ulcerative colitis, abdominal pain is a more frequent 
and  persistent  complaint.  Pain  may  be  intermittent  and  colicky  or 
sustained  and  severe  and  is  attributable  to  inflammation,  abscess  and 
obstruction.  In  contrast  with  ulcerative  colitis,  gross  rectal  bleeding  is 
uncommon  and  acute  hemorrhage  is  rare72.  Constitutional  symptoms, 
particularly weight loss and fever, or growth retardation in children, may 
be prominent and occasionally are the sole presenting features of Crohn's 
disease.  Crohn's  disease  may  be  divided  roughly  into  two  categories: 
aggressive fistulizing disease and indolent cicatrizing disease denoted by 
fibrostenotic stricture73; a third subset of patients appear to develop neither 
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behaviour  over  long  periods  of  observation.  Fistulas  are  frequent 
manifestations  of  the  transmural  nature  of  Crohn's  disease.  Perianal 
fistulas are common and are estimated to occur in 15% to 35% of patients. 
Strictures  represent  long standing  inflammation  and may  occur  in  any 
segment  of  the  gastrointestinal  tract  in  which  inflammation  has  been 
active.  Diarrhoea  is  the  most  common complaint  among patients  with 
Crohn's  disease.  Increased  stool  frequency  and  decreased  stool 
consistency arise  through alterations in mucosal  function and intestinal 
motility. Pathophysiology of abdominal pain in due to stretch receptors in 
the bowel wall which may be stimulated as a food bolus passes through 
stenotic bowel, leading to abdominal pain and possibly vomiting. Visceral 
pain  may  result  from inflammation  of  the  serosa.  The  ganglia  of  the 
myenteric plexuses in the intestine in Crohn's disease have been noted to 
be  increased  in  size  and  number,  possibly  indicating  neural 
dysfunction74.Weight loss and malnutrition are often seen in patients with 
Crohn's disease and contribute to weakness, irritability, malaise and easy 
fatigability that are so common. Anorexia, nausea and vomiting also may 
contribute to weight loss and poor nutrition. Fever associated with active 
Crohn's  disease  usually  is  low  grade  and  may  occasionally  be  the 
presenting  complaint.  Anaemia  is  found  in  one  third  of  patients  with 
Crohn's disease, primarily as a consequence of iron deficiency from blood 
loss.
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ULCERATIVE COLITIS
          The symptom complex tends to differ according to the extent of 
disease75. Patients with proctitis often have local symptoms of tenesmus, 
urgency, mucus and bleeding, whereas patients with extensive colitis may 
have more diarrhea, weight loss,  fever, clinically significant blood loss 
and abdominal pain. The median interval between the onset of symptoms 
and  diagnosis  of  UC  is  approximately  9  months76.Rectal  bleeding  is 
common in UC. The characteristic of the bleeding is determined by the 
location of the disease. Patients with proctitis usually complain of passing 
fresh blood, either separately from the stool or streaked on the surface of a 
normal  or  hard stool77.  Mixture of  blood and mucus and may even be 
incontinent. Diarrhoea is common but not always present. There can be 
frequent passage of loose or liquid stools and some may have nocturnal 
diarrhea.  Fecal  urgency,  sensation  of  incomplete  evacuation  and  fecal 
incontinence are  also common.  With left-sided disease,  distal  transit  is 
rapid,  but  there  is  actual  slowing of  proximal  transit,  which may help 
explain  the  constipation  that  is  commonly  seen  in  patients  with  distal 
colitis. Vague lower abdominal discomfort, an ache in the left iliac fosse 
or  intermittent  abdominal  cramping  preceding  bowel  movements  and 
often  persisting  transiently  after  defecation.  Severe  cramping  and 
abdominal pain and vomiting can occur in association with severe attacks 
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of the disease. These symptoms, as well as protein loss through inflamed 
mucosa,  hypercatabolism  and  downregulation  of  albumin  synthesis 
caused  by  the  inflammation,  account  for  weight  loss  and 
hypoalbuminemia.  Fever,  an  additional  catabolic  factor,  usually 
accompanies severe attacks but is typically of a moderate degree. Patients 
also  may  complain  of  symptoms from anaemia  and hypoalbuminemia, 
including  fatigue,  dyspnea  and  peripheral  edema.  A few  patients  may 
present  with  extra  intestinal  manifestations  such  as  acute  arthropathy, 
episcleritis and erythema nodosum. Patients with severe attacks also may 
appear  well,  but  most  are  ill  with  tachycardia,  fever,  orthostasis  and 
weight  loss.  The abdomen typically  is  soft  with only  mild  tenderness. 
Abdominal  tenderness  may  become  diffuse  and  moderate  with  more 
severe disease. Bowel sounds may be normal or hyperactive but diminish 
with progressive disease. In fulminant colitis, the abdomen often becomes 
distended  and  firm,  with  absent  bowel  sounds  and  signs  of  peritoneal 
inflammation.  There  may  be  aphthoid  ulceration  of  the  oral  mucosa. 
Clubbing of the fingernails is a frequent manifestation of chronic disease. 
Peripheral  edema  may  occur  secondary  to  hypoalbuminemia.  Minor 
perianal disease may be present. Signs of extra intestinal manifestations 
also may be present.
V.ASSESMENT OF SEVERITY OF IBD
CROHN’S DISEASE
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Working definition of Crohn’s disease activity
MILD TO MODERATE DISEASE
The patient is ambulatory and able to take oral alimentation .
No  dehydration,  high  fever,  abdominal  tenderness,  painful  mass, 
obstruction weight loss less than 10%
MODERATE TO SEVERE DISEASE
Either the patient has failed treatment for mild to moderate disease 
More  pronounced  symptoms  including  fever,  significant  weight  loss, 
abdominal  pain  or  tenderness,  intermittent  nausea  and  vomiting,  or 
significant anemia
SEVERE FULMINANT DISEASE
Either the patient has symptoms despite outpatient steroid therapy
High fever,  persistent  vomiting,  and evidence  of  intestinal  obstruction, 
rebound tenderness, cachexia or evidence of an abscess.
ULCERATIVE COLITIS
Truelove and Witts classification
MILD
<4 stools /day, without or with only small amounts of blood
No fever
No tachycardia
Mild anemia
ESR <30mm/hr
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MODERATE
Intermediate between mild and severe
SEVERE
>6 stools /day, with blood
Fever>37.5 C
Heart beat>90 beats/min
Anemia with hemoglobin<75% of normal
ESR.30mm/hr
VI. LABORATORY FINDINGS
       Anaemia, leukocytosis and thrombocytosis, reflect active disease. 
Iron deficiency anaemia may be present because of chronic blood loss. 
Hypoalbuminemia  may  be  seen  with  both  acute  and  chronic  disease. 
Minor elevations in serum levels of aspartate aminotransferase or alkaline 
phosphatase also are frequently associated with severe disease, but these 
changes are transient and return to normal when the disease enters into 
remission.  These  abnormalities  probably  reflect  a  combination  of  fatty 
liver, sepsis, and poor nutrition. Serum inflammatory markers including 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) may 
be elevated in active disease. For following clinical changes, CRP is more 
sensitive than ESR because of the shorter half-life of CRP.
29
VII.ESTABLISHING THE DIAGNOSIS AND 
EVALUATION OF DISEASE
CROHN’S   DISEASE
              No single symptom, sign, or diagnostic test establishes the 
diagnosis of Crohn's disease. Rather the diagnosis is established through a 
total assessment of the clinical presentation with confirmatory evidence 
from radiologic, endoscopic, and in most cases, pathologic findings. Stool 
studies  should  include  culture,  examination  for  ova  and parasites,  and 
testing  for  Clostridium difficile  toxin  and  should  be  performed before 
endoscopy or barium studies. Serology for Entamoeba histolytica should 
be considered in selected patients.  Ultimately,  the diagnosis of Crohn's 
disease  is  confirmed  by  findings  on  barium  studies,  endoscopy  and 
usually histopathology. Barium studies are especially useful to delineate 
the late transmural complications of Crohn's disease, but typical findings 
may be seen early in the disease as well. Early findings include aphthous 
ulcers, a coarse villus mucosal pattern and thickened folds78. Submucosal 
edema  may  be  evident  as  thickening  or  flattening  of  the  valvulae 
conniventes,  whereas  transmural  edema  manifests  as  widening  of  the 
separation  between  bowel  loops.  Later  findings  include  a  cobblestone 
appearance resulting from edema and inflammation of relatively spared 
islands of mucosa separated by intersecting longitudinal  and transverse 
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knifelike clefts of ulceration78. Still later, one may discern fistulas, sinus 
tracts, and fixed strictures.
ULCERATIVE COLITIS  
The  diagnosis  relies  on  a  combination  of  compatible  clinical  features, 
endoscopic appearances and histologic findings. Stool cultures should be 
obtained to exclude infection with routine bacterial pathogenic organisms; 
assays for toxins A and B of  C. difficile and examinations for ova and 
parasites  also  should  be  performed.  Infection  with  Escherichia  coli 
O157:H7 should  be  considered and  requires  special  stool  cultures  and 
special  cultures  for  gonococcus  or  Chlamydia may  be  necessary  in 
selected  cases.  In  patients  presenting  with  their  first  attack  of  UC, 
sigmoidoscopy with biopsies usually is sufficient to confirm the diagnosis. 
The  hallmark of  UC is  symmetrical  and continuous inflammation that 
begins in the rectum and extends proximally without interruption for the 
entire extent of disease. The earliest endoscopic sign of UC is a decrease 
or loss of the normal vascular pattern, with erythema and edema of the 
mucosa.. With more severe inflammation, the mucosa may be covered by 
yellow-brown  mucopurulent  exudates  associated  with  mucosal 
ulcerations.  Severe  UC  is  associated  with  mucosa  that  bleeds 
spontaneously, and there may be extensive areas of denuded mucosa from 
severe  mucosal  ulcerations  with  diffuse  colitis  .In  long  standing  UC 
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pseudopolyps  may  be  present.  Barium  studies  of  the  colon  remain 
important, however, and may be superior to colonoscopy for evaluation of 
colonic strictures. The earliest radiologic change of UC seen on barium 
studies is fine mucosal granularity. With increasing severity, the mucosal 
line  becomes  thickened  and  irregular,  and  superficial  ulcers  are  well 
shown en face.  Deep ulceration can appear as  “collar-stud” or  “collar-
button” ulcers .
EXTRAINTESTINAL MANIFESTATIONS  
CROHN’S DISEASE
           It is estimated that one fourth of all patients with Crohn's disease 
will  have  an  extra  intestinal  manifestation  of  IBD79.  Many  of  these 
complications are common to both Crohn's disease and ulcerative colitis 
and indeed to other nonidiopathic inflammatory conditions of the bowel. 
In Crohn's disease, the major risk factor for this complication appears to 
be the number of prior ileal resections80. In large series, extra intestinal 
manifestations are found to occur more frequently in Crohn's disease than 
in ulcerative colitis and are more common among patients with colonic 
involvement than in patients with no colonic inflammation. One fourth of 
those affected will  have more than one manifestation81,82.  Conceptually, 
these  extra  intestinal  manifestations  may  be  categorized  as  those 
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associated with small bowel disease or large bowel disease and those that 
occur in association with active bowel disease or independent of the state 
of inflammation. Some complications occur as a direct result of the bowel 
disease, such as nephrolithiasis resulting from oxalate malabsorption. In 
the case of inflammatory mucocutaneous, joint, and ocular manifestations, 
the pathogenesis is an influx of mononuclear cells activated in the gut, but 
homing aberrantly to the involved extra intestinal organs83.
MUSCULOSKELETAL MANIFESTATIONS
       Among the most common extra intestinal manifestations are disorders 
of  the bones  and joints.  Clubbing of  the fingernails  is  a  common and 
innocuous finding. More consequential are arthritic manifestations, which 
are  observed  more  frequently  in  patients  with  Crohn's  disease  than in 
those with ulcerative colitis.  In a study of 976 patients with ulcerative 
colitis and 483 patients with Crohn's disease, pauciarticular arthropathy 
(type I, affecting four or fewer joints) occurred in 3.6% of patients with 
ulcerative colitis  and in 6.0% of those with Crohn's  disease84.  In most 
patients,  joint  symptoms occurred  in  the  setting  of  a  relapse  of  bowel 
symptoms.  Polyarticular  arthropathy  (type  II,  with  five  or  more  joints 
affected) occurred in 2.5% of patients with ulcerative colitis and 4.0% of 
those with Crohn's disease84. Among patients with Crohn's disease, nearly 
one  half  had  joint  symptoms  in  association  with  a  relapse  in  bowel 
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disease.  Distinct HLA genotypes are associated with these two types of 
peripheral arthropathy—type I: HLA-DRB1*0103, B*35 and B*27; and 
type  II:  HLA-B*4485.  Peripheral  arthralgias  occur  in  16%  to  20%  of 
patients with Crohn's disease82, most strongly in association with colonic 
disease. Patients tend to have waxing and waning joint pain and stiffness 
in association with flares of bowel disease. Joints may be involved in an 
asymmetrical or migratory fashion. Usually, the disease is nondeforming 
and often is accompanied by skin complications (erythema nodosum) and 
eye  complications  (uveitis).  Rheumatoid  factor  typically  is  negative  in 
these patients. Knee and ankle joints often are affected first, but elbows, 
wrists,  proximal  interphalangeal,  metacarpophalangeal  and 
metatarsophalangeal joints may be involved subsequently86. Patients who 
have undergone ileocecal resection for their disease tend to have fewer 
arthritic complications after their surgery87.
        Axial arthropathies are less common than peripheral arthropathies 
and occur in 3% to 6% of patients with IBD. Spondylitis associated with 
IBD, like idiopathic ankylosing spondylitis, presents as insidious low back 
pain and morning stiffness that is improved by exercise. As many as 75% 
of patients with Crohn's disease and spondylitis may be positive for HLA-
B27.  Iritis  may  occur  in  association  with  this  manifestation.  Bilateral 
symmetrical  sacroiliitis  without  progression  to  spondylitis  is  more 
common  than  spondylitis  and  is  reported  to  occur  in  4%  to  18%  of 
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patients86. In one study, radiologic findings of sacroiliitis were detected in 
29% of patients with Crohn's disease, although only 3% had symptoms of 
sacroiliitis88.
       More  rare  rheumatologic  complications  include  granulomatous 
vasculitis89, periostitis,  amyloidosis and septic joint.  Aseptic necrosis of 
the  hip  and  other  joints  may  occur  with  or  without  the  use  of 
glucocorticoids  and  may  be  disabling90.  Osteomyelitis  may  occur  as  a 
result of direct extension by a fistula, usually to the pelvis, or may be a 
recurrent  problem  distant  from  the  site  of  inflammation,  presumably 
through hematogenous spread of bacteria91.
      Metabolic bone disease is common in Crohn's disease; osteopenia 
or  osteoporosis  occurs  in  30%  to  60%  of  patients.  Morbidity  as  a 
consequence  of  increased  susceptibility  to  bone  fractures  includes 
debilitating and painful vertebral crush fractures, which may occur even in 
children with Crohn's disease.
MUCOCUTANEOUS MANIFESTATIONS
         The most common skin lesions associated with IBD are pyoderma 
gangrenosum and erythema nodosum. Neither condition is found solely in 
IBD, and the finding of one or the other lesion is not specific for either 
major form of IBD92. Pyoderma gangrenosum appears first as a papule, 
pustule or nodule, most often on the leg or occasionally around a stoma, 
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and  progresses  to  an  ulcer  with  undermined  borders.  Pyoderma  may, 
however, occur virtually anywhere on the body. The ulcer typically has a 
violaceous rim and crater-like holes pitting the base. The phenomenon of 
pathergy, or the development of large ulcers in response to minor trauma, 
is  characteristic  of  pyoderma  gangrenosum  and  the  skin  lesions  of 
Behçet's syndrome93. Healing is associated with a classically cribriform, 
or pocked, scar. In Crohn's disease , pyoderma gangrenosum often occurs 
without an associated flare of bowel symptoms.
         In  contrast  with  pyoderma  gangrenosum,  erythema  nodosum  is 
much more frequently seen in women than in men. The classic appearance 
is  of  tender  subcutaneous  nodules  with  an  erythematous  or  dusky 
appearance,  most  often  seen on the  pretibial  region.  There is  a  strong 
association  with  arthropathy.  Erythema  nodosum often  presents  during 
exacerbations of bowel disease and tends to improve with treatment of the 
underlying bowel disease..
         Aphthous ulcers  of  the  mouth  are  common among patients  with 
Crohn's disease and ulcerative colitis but are also frequently seen among 
otherwise  healthy  persons94.  Angular  cheilitis  is  seen  in  nearly  8% of 
patients with Crohn's disease94.
        A rare manifestation is metastatic Crohn's disease, granulomatous 
inflammation  of  the  skin  remote  from  the  gastrointestinal  tract  , 
histologically  identical  to  the  primary  bowel  lesion95.  Described  cases 
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have included lesions behind the ears, in the perineum and on the legs, 
penis, and vulva. Other rare skin manifestations of Crohn's disease include 
leukocytoclastic  vasculitis96,  Sweet's  syndrome  (neutrophilic 
dermatosis)97,  cutaneous polyarteritis  nodosa  and epidermolysis  bullosa 
acquisita.  Some  reports  have  suggested  an  increased  occurrence  of 
psoriasis among patients with Crohn's disease98.
OCULAR MANIFESTATIONS
        Ocular manifestations are estimated to occur in 6% of patients with 
Crohn's disease99. Episcleritis is more common in Crohn's disease than in 
ulcerative colitis, consists of injection of the sclera and conjunctiva, and 
does not affect visual acuity. Episodes tend to occur in association with 
active bowel disease. Scleritis involves deeper layers of the eye and also 
occurs most  often in parallel  with active bowel disease but may cause 
lasting damage if untreated. Uveitis usually presents with headache, deep 
eye pain, lacrimation, blurred vision and photophobia, as a consequence 
of iridospasm. Physical examination findings include miosis and ciliary 
flush.  Visual  acuity  is  preserved unless the posterior  segment  becomes 
involved.  In  contrast  with  the  uveitis  associated  with  ankylosing 
spondylitis,  the  presentation  of  uveitis  in  patients  with  IBD  often  is 
insidious,  with  bilateral  involvement  and  extension  to  the  posterior 
segment100. Slit-lamp examination demonstrates an inflammatory “flare” 
in the anterior chamber.. Other ocular complications of Crohn's disease 
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include a particular  corneal  injury referred to as keratopathy and night 
blindness resulting from malabsorption of vitamin A.
HEPATOBILIARY MANIFESTATIONS
         Gallstones are found in more than 25% of men and women with 
Crohn's disease. Asymptomatic and mild elevations of liver biochemical 
tests often are seen in Crohn's disease, but few of these patients develop 
clinical evidence of cirrhosis. Primary sclerosing cholangitis(PSC) more 
often is associated with ulcerative colitis but may occur in 4% of patients 
with  Crohn's  disease,  usually  those  with  colonic  involvement101.  In 
patients with Crohn's disease, the inflammatory changes most often are 
confined to the small biliary radicals and, therefore, the presentation is 
usually one of abnormal liver biochemical tests, pericholangitis on liver 
biopsy, and a normal cholangiogram101. Other hepatobiliary complications 
of Crohn's disease include fatty liver and autoimmune hepatitis.
RENAL AND GENITOURINARY MANIFESTATIONS
       In  addition  to  the  direct  complications  of  perforating  Crohn's 
disease  with  encroachment  on  the  bladder  and  other  genitourinary 
structures  and  inflammatory  entrapment  of  the  ureter,  uric  acid  and 
oxalate stones are common in patients with Crohn's disease. In the setting 
of fat malabsorption resulting from intestinal resection or extensive small 
bowel disease, luminal calcium binds free fatty acids, thereby decreasing 
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the calcium that is available to bind and clear oxalate. Increased oxalate is 
absorbed  as  the  sodium  salt,  resulting  in  hyperoxaluria  and  calcium 
oxalate  stone  formation.  Uric  acid  stones  are  believed  to  result  from 
volume depletion and a  hypermetabolic  state.  More  rare  complications 
include  membranous  nephropathy,  glomerulonephritis  and  renal 
amyloidosis.  Penile and vulvar edema also have been reported, but the 
mechanism for these occurrences is unknown.
COAGULATION AND VASCULAR COMPLICATIONS
       A prothrombotic tendency has been noted in both major forms of 
IBD. Patients may present with venous thromboembolism or, much less 
commonly, arterial thrombosis. The hypercoagulable state may arise from 
many possible causes. Contributing factors may include thrombocytosis; 
increased levels of fibrinogen, fibrinopeptide A, factor V and factor VIII; 
antithrombin III deficiency; and free protein S deficiency; all are related 
to active bowel inflammation. Circulating immune complexes, increased 
levels  of  plasminogen  activator  inhibitors,  decreased  levels  of  tissue 
plasminogen  activator  and  spontaneous  platelet  aggregation  may  be 
present independent of bowel inflammation. Increased prevalence of the 
factor  V Leiden  mutation  has  been observed by  some102 but  not  other 
investigators103.  Defective  methylenetetrahydrofolate  reductase  is  more 
prevalent among patients with IBD than it is in the general population104. 
This finding, along with folate and vitamin B12 deficiency, is linked to 
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hyperhomocysteinemia, which in turn predisposes to thrombosis. In more 
than  one  half  of  patients  who  experience  thrombosis,  however,  no 
predisposing factor can be identified105.
OTHER MANIFESTATIONS  
           Clinically significant disease of the lungs106, heart, pancreas and 
nervous  system107 in  association  with  Crohn's  disease  is  unusual,  but 
reported. Subclinical lung involvement may be much more common than 
is  apparent,  perhaps reflecting the commonality  of  bronchus-associated 
lymphoid tissue and gut-associated lymphoid tissue106.  Cardiomyopathy 
may result from a variety of nutrient deficiencies in patients with marked 
malabsorption. Pleuropericarditis, myocarditis and endocarditis may occur 
rarely108.  Acute  pancreatitis109,  granulomatous  pancreatitis110 and 
pancreatic insufficiency111 also have been reported. 
EXTRAINTESTINAL MANIFESTATIONS  
ULCERATIVE COLITIS
      These extraintestinal complications are  classified by their relations 
to the activity of the colitis. Manifestations that parallel disease activity 
usually improve on treatment of the colitis.
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DERMATOLOGIC 
The most common skin manifestations of UC are complications of 
drug treatment  which   include  hyper-sensitivity,  photosensitivity  and 
urticarial  rashes  related  to  sulfasalazine  and  less  commonly  to 
mesalamines. Others are erythema nodosum and pyoderma  gangrenosum. 
Erythema nodosum occurs in 2% to 4% of patients with  UC. Its activity 
typically parallels the activity of the underlying bowel  disease. Pyoderma 
gangrenosum  occurs in 1% to 2% of patients. It is  usually related to the 
activity  of  colitis  but  may  present  or  persist  despite  inactive  bowel 
disease.  Other less common manifestations associated with UC include 
Sweet's syndrome or acute febrile neutrophilic dermatosis and pyodermite 
végétante Hallopeau.
OCULAR 
The two most common ocular manifestations associated with UC 
are  episcleritis and uveitis, occurring in 5% to 8% of patients. Episcleritis 
typically  parallels  the  activity  of  bowel  disease.  In  contrast,  temporal 
correlation of uveitis with the activity of the colitis is less predictable than 
with episcleritis. 
ORAL 
At least 10% of patients with UC, develop oral  aphthous ulcers. 
These  lesions usually occur with flares of colitis and resolve on control of 
the  bowel disease. Angular stomatitis and sore tongue are seen in patients 
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with deficiencies of iron or other micronutrients A rare oral lesion  seen in 
patients with UC is pyostomatitis (pyoderma) vegetans. 
MUSCULOSKELETAL 
Musculoskeletal  abnormalities  associated  with  UC can  be  either 
rheumatologic  disorders  or  metabolic  bone  diseases.  Peripheral 
arthropathy  occurs  in  5%  to  20%  of  patients  with  UC.  The  risk  of 
arthropathy  increases  with  the  extent  of  colonic  disease.  Peripheral 
arthropathy  can  be  classified  into  two  distinct  types112.Type  1  is 
asymmetrical  and  pauciarticular,  affecting  fewer  than  five  joints  and 
typically  involving  the  large  joints.  It  parallel  the  underlying  bowel 
disease  activity.  Type  2  arthropathy  is  symmetrical  and  polyarticular, 
affecting five or more joints and typically involving the small joints.  This 
type presents with persistent symptoms independent of the colitis  activity. 
   Axial arthropathy occurs less frequently  in patients with UC, and 
includes sacroiliitis and spondylitis. Isolated sacroiliitis occurs in 10% to 
15% of patients.  It  does not  usually  parallel  the activity of the bowel 
disease. The typical symptom is low back pain. Ankylosing spondylitis 
occurs in 1% to 2% of patients with UC, and most of these patients are 
HLA-B27  positive.  Patients  with  UC may  develop  low bone  mineral 
density  due   to  several  factors,  including  glucocorticoid  therapy,  low 
physical  activity,  and   inflammatory  cytokines.  Osteonecrosis  or 
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avascular or  aseptic necrosis of bone or  osteochondritis  dissecans, is a 
less common but serious complication in patients with UC. 
HEPATOBILIARY 
Mild  elevations  in  serum  aminotransferase  and  alkaline 
phosphatase  levels  are  common  in  severe  attacks  of  UC.  These 
abnormalities are due  be related to a combination of factors, including 
malnutrition,  sepsis  and  fatty  liver.  The  most  important  hepatobiliary 
complication associated  with UC is PSC, which occurs in approximately 
3% of patients . PSC should be excluded in patients with UC who have 
persistently abnormal liver tests or evidence of chronic liver disease. PSC 
is  independent  of  the   underlying  colitis  and  it  usually  follows  a 
progressive course after many years of stable disease. 
HEMATOLOGIC 
The  occurrence  of  hypercoagulability  in  UC   most  commonly 
manifest as  deep venous thrombosis or pulmonary embolism; renal artery 
thrombosis,  cerebrovascular  accidents,  coronary  artery  thrombosis  and 
venous  thrombosis  of  mesenteric,  portal,  and  hepatic  vessels  all  have 
been reported113,114,115.A variety of coagulation and platelet abnormalities 
may  be  present  in  patients  with  UC,  and  include  thrombocytosis; 
increased  levels  of  fibrinogen,  coagulation  factors  V  and  VIII  and 
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plasminogen activatorinhibitor; and decreased levels of antithrombin III, 
proteins  C  and  S,  factor  V Leiden,  and  tissue  plasminogen  activator. 
There   may  be  an  increased  incidence  of  factor  VLeiden  mutation  in 
patients with thromboembolic complications associated with UC. 116,117,118 
Another  common hematologic  complication  is  anemia.  The anemia  in 
patients with UC may be a result of chronic gastrointestinal blood loss, 
chronic  disease,  folate  deficiency  from  sulfasalazine  therapy  or 
autoimmune hemolysis. Autoimmunehemolytic anemia, usually Coombs 
positive, may be related to sepsis or glucose-6-phosphate dehydrogenase 
deficiency in patients on sulfasalazine.
OTHER MANIFESTATIONS 
Secondary systemic amyloidosis is a rare but serious complication 
associated  with  UC.119 Pericarditis,  Pleuropericarditis   and constrictive 
pericarditis  have been reported in patients with UC,120,121,122,123  although 
this  complication  also  may  be  related  to  mesalamine    therapy.124,125 
Patients with UC may also develop  abnormalities in pulmonary function, 
including an increase in  functional  reserve capacity  and a  decrease  in 
diffusion capacity.126 Other  pulmonary diseases that  have been described 
in  patients  with  UC  include   bronchiectasis,  bronchiolitis,  fibrosing 
alveolitis, pulmonary fibrosis and pulmonary vasculitis.127,128,129
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AIMS AND OBJECTIVES
(1) To study the clinical presentation of IBD in our hospital.
(2) To study the extra intestinal manifestations of inflammatory bowel 
disease
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MATERIALS AND METHODS
Setting                      : Department of Medicine,  Govt Rajaji Hospital
Design                      : Descriptive study
Period of study         :  Ten  months (January2009-October2009)
Ethical approval       : Obtained from ethical committee approval headed 
                                    by Dean, Govt. Rajaji Hospital
Consent                     : Obtained from all patients
Statistical software   : EPI Info 2008
Study population      : Patients attending Gastroenterology OPD with 
                                    bleeding PR who satisfied the inclusion 
                                    criteria.
Inclusion criteria:
(1) All cases of bleeding PR who satisfied the clinical, colonoscopic 
and histologic criteria of IBD were included.
(2) All cases of proven UC were also included.
Exclusion criteria:
(1) Positive   results  for  stool  culture,  ova  and  parasites  and 
clostridium difficile toxin
(2) Patients with known rheumatological diseases.
(3) Patients with chronic alcoholism.
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           Thirty nine patients of ulcerative colitis were selected from 
Gastroenterology  OP,  Govt.  Rajaji  hospital,  Madurai,  presenting  with 
complains  of  bleeding  PR  and  those  who  satisfied  the  clinical, 
colonoscopic and histologic criteria for IBD  .
          The duration of illness was upto 10 years, at different stages of 
Inflammatory bowel disease. Patients with the age group ranging from 15 
to 70 years were studied.
The  selected  patients  were  evaluated  with  detailed  history 
regarding duration of disease and symptomatology.
Detailed clinical examination was done. Vitals and temperature of 
patients were recorded. All systems are examined carefully . 
          Colonoscopic examination  of these patients were done after taking 
proper  consent.  Biopsy  specimens  were  taken  and  sent  to  Pathology 
Department  of  Govt.  Rajaji  hospital,  Madurai  for  histopathological 
examination.  Extent of the disease was determined by colonoscopy and 
was  classified  as  distal  proctitis,  proctosigmoiditis,  left-sided  colitis 
(involvement up to splenic flexure) and pancolitis. Severity was assessed 
using Truelove & Witts criteria. Cases were examined for extraintestinal 
manifestations. Routine investigations were taken .Liver function tests of 
these patients were sent. Ultrasound scan of abdomen was done to know 
the incidence of fatty liver and gallstones at the Radiology Department. 
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Musculoskeletal manifestations and Dermatological manifestations were 
noted . Slit lamp examination of eye was done to look for evidence of 
uveitis. 
The  information  collected  regarding  all  the  selected  cases  were 
recorded in  a  Master  Chart.  Data  analysis  was  done with the  help of 
computer using Epidemiological Information Package (EPI 2008).
Using  this  software  range,  frequencies,  percentages,  means, 
standard deviations were calculated. 
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RESULTS AND ANALYSIS OF OBSERVED DATA
 A : CHARACTERISTICS  OF  CASES  STUDIED
Table 1 : Age distribution of cases
AGE GROUP
CASES
No. %
Upto 20 year 5 12.8
21-30 years 4 10.3
31 – 40 years 13 33.3
41 – 50 years 5 12.8
> 50 years 12 30.8
Total 39 100
Range
Mean
S.D.
16 – 67 years
40.8 years
 14.3 years
The age group most seen in our study was between 31-40 years.
          Table 2  : Sex distribution
Sex
CASES
No. %
Male 11 28.2
Female 28 71.8
Total 39 100
Table 3 : Quantitative parameters
Parameter
Normal cases Abnormal 
cases Range Mean S.D.
No. % No. %
Hb.% 11 28.2 28 71.8 4.8-13.2 9.96 1.81
TOTAL WBC 26 66.67 13 33.33 6.2-18.7 9.7 3.3
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COUNT
ERYTHROCYTE 
SEDIMENTATION 
RATE
11 28.2 28 71.2 20-145 64.1 35.1
PLATELET 28 71.2 11 28.2 1.25-5.17 2.82 0.86
FIBRINOGEN 39 100 - - 114-450 186 75
AMYLASE 29 74.4 10 25.6 34-185 78.7 44.6
BILIRUBIN 39 100 - - 0.3-1.1 0.85 0.14
AST & ALT 34 87.2 5 12.8 12-46 23.1 9.2
ALP 39 100 - - 90-382 158.9 61.7
TOTAL PROTEIN 32 82.1 7 17.9 4.4-7.5 6.45 0.79
ALBUMIN 31 79.5 8 20.5 2.3-4.8 3.59 0.61
GLOBULIN 34 87.2 5 12.8 2.1-3.5 2.86 0.35
In  this  study  71.8%of  patients  were  anaemic  and  71.2%were  
having  elevated  ESR.  There  was  no  significant  elevation  of   alkaline  
phosphatase noted.
 
Table    4 :      Colonoscopy findings
Colonoscopy findings
CASES
No. %
IBD – CD 2 5.1
IBD –UC 37 94.9
Total 39 100
Of the total of 39 patients , 37 had evidence of Ulcerative colitis and 2 
were diagnosed with Crohn’s disease by biopsy.
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Table     5: Biopsy results
Biopsy Findings
CASES
No. %
Non Caseating granuloma 2 5.1
Active Ulcerative Colitis 37 94.9
Total 39 100
Biopsy of the cases showed non caseating granulomas in Crohn’s 
disease and evidence of active Ulcerative colitis in the rest.
Table     6: Truelove & Witts Criteria for disease severity
Truelove & Witts
CASES
No. %
Mild 1 2.7
Intermediate 6 16.2
Severe 30 81.1
Total 37* 100
* Two cases are Non Caseating granuloma
Table     7: Extent of disease
Extent of disease
CASES
No. %
Distal Proctitis (DP) 5 12.8
Distal Procto Sigmoiditis (DPS) 3 7.7
Splenic Flexure (SF) 9 23.1
Total Colitis (TC) 20 51.3
Terminal Ileum & Colon (TIC) 2 5.1
Total 39 100
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Out of the 37 cases of UC, 51.3% had evidence of total colitis, followed 
by involvement upto splenic flexure in 23.1%, distal proctitis in 12.8% 
and  distal proctosigmoiditis in 7.7%. 
Table     8: USG Findings
USG Findings
CASES
Normal Abnormal
No % No %
Fatty liver 30 76.9 9 23.1
Gall stones
TOTAL
35 89.7 4
13
10.3
33.3
Fatty liver was the predominant hepatobiliary manifestation in our study
 in 23.1%.
 Table 9:  Musculoskeletal manifestations
Musculoskeletal
CASES
Present Absent
No % No
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Low Backache ( L)
Pauciarticular (P)
Polyarticular (Py)
TOTAL
10
10
3
23
25.
6
25.
6
7.6
9
58.
8
29
29
36
74.4
74.4
92.3
Pauciarthalgia was the most common musculoskeletal manifestation seen.
Table     10: Mucocutaneous manifestations
Mucocutaneous
CASES
Present Absent
No % No %
Angular Stomatitis ( AS)
Pyoderma Gangrenosum (PG)
Aphthous ulcer (AU)
Erythema Nodosum(EN)
TOTAL    SKIN (EN+PG)
TOTAL MUCOSAL (AU + AS)
6
1
2
1
2
8
15.3
8
2.56
5.12
2.56
5.12
20.5
33
38
37
38
37
31
74.62
97.4
94.87
97.4
94.8
79.5
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Angular stomatitis was the most seen mucocutaneous manifestation in
 our study.   We had 2.56% each of erythema nodosum and pyoderma 
gangrenosum in our study.
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DISCUSSION
39  patients  of   IBD  from  Gastroenterology  Department  are 
analysed .Our study has 37 cases of UC and 2 cases of CD.
Of the 37 cases of UC,81% of  cases are severe,16% intermediate 
and 2.6% classified as mild according to the Truelove & Witts criteria. 
Total colitis is seen in 51.3% of cases followed by left sided colitis in 
23.1% , distal proctitis in 12.8% , distal proctosigmoiditis in 7.7%. 
Sex ratio of IBD in this study is 1:2.5 . The sex ratio for UC is 
1:2.4.According  to  Harrisons  Text  Book  of  Internal  Medicine  the  sex 
ratio for UC is 1:1 and for CD is 1.1:1.8.
Sleisenger  Text Book of Gastroenterology shows a  small  excess 
risk of Crohn's disease among women and a female-to-male ratio between 
unity and 1.2:1. Most studies have not shown any gender difference in the 
occurrence of UC and a male-to-female ratio of nearly 1:1 applies to all 
age groups.
The age group with maximum prevalence of disease in our study is 
31-40 years. The peak incidence of UC occurs in the 2nd and 3rd decades 
of life and had a second peak incidence above 50 years of age.  According 
to Sleisenger, UC may present at all ages, although diagnosis before the 
age of 5 years or after 75 years is uncommon .Studies have  reported a 
second, smaller peak in the elderly, between the ages of 60 and  70 years. 
This  second  peak  is  less  pronounced  than  that  for  Crohn's   disease. 
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Crohn's disease is diagnosed mostly among persons aged 15 to  30 years, 
although the age of diagnosis may range from early childhood  through 
the entire lifespan. Population-based studies have shown the median age 
of diagnosis to be approximately 30 years. 
Of the 39 patients, 25 patients  have anyone of the extraintestinal 
features,  which is  64% in our  study.Below is  the list  of  frequency of 
extraintestinal manifestations in our study compared with published data.
EXTRAINTESTINAL 
MANIFESTATIONS
OUR STUDY REFERENCE STUDY
SEX 1:2.5 1:1.8(CD),1:2.4(UC)
AGE GROUP 31-40 YRS 2ND & 3RD Decade
FATTY LIVER 23.1% 15.4% (Navneethan et al)
GALL STONES 10.3% 10.5%(Kurchin A et al)
PAUCI ARTHRALGIA 25.6% 16% (Brinskow et al)
POLYARTHRALGIA 7.69% 6.5% (Brinskow et al)
LOW BACK ACHE 25.6% 4-18%(CD),10-15%(UC)
ERYTHEMA NODOSUM 2.6% 4.0% (Fahri et al)
PYODERMA 
GANGRENOSUM
2.6% 2.3% (Yuskel et el)
ANGULAR STOMATITIS 15.38%  8%(CD)
APTHOUS ULCER 5.12% 10%(UC)
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FATTY LIVER.
In a study by  Navaneethan U130,  Remzi FH et al ,a total of 545 
Ileal  Pouch  Anal  Anastomosis  patients  with  underlying  IBD  which 
included  346  patients  with  ulcerative  colitis,  25  with  indeterminate 
colitis, and 2 with Crohn's colitis, a total of 17.4% had abnormal LFTs. 
Of these patients,13.9% had abnormal transaminases. The most common 
cause  of  an  abnormal  LFT was  transient  elevation  in  49.2% patients, 
followed by fatty liver (fatty change on imaging with body mass index 
(BMI) >/=25 kg/m(2) in the absence of other causes, including alcohol 
abuse and drug-induced hepatitis) in 15.4%, drug-induced abnormal LFTs 
in 7 (10.7%), and chronic hepatitis B or C in 6 (9.2%). 
      Harrison    says  Fatty  liver   is  detected  in  more  than  50%of 
abnormal liver biopsies in IBD. 
      In our study the incidence is 23.1% and is comparable to the above 
data.
GALL STONES   
Our study, the gall stone incidence is 10.3%.Gall stones are present 
in both cases of CD and percentage of UC patients  with Gallstones is 
5.4%.
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In a  study by  Kurchin A, et  al131 ,a  retrospective study of  152 
ileostomates with inflammatory bowel disease (IBD) revealed that  10.5 
per cent had diagnoses of cholelithiasis. The remaining patients,   were 
followed for  possible cholelithiasis,  with sonographic examination and 
23.2  percent  were  found  to  have  cholelithiasis,  usually  in  an 
asymptomatic stage. Among women over 50 years old,  (63.6 per cent) 
had gallstones.
Harrison says 10-35%of patients with ileitis or ileal resection have 
gall stones and that it is more associated with CD.
In a study by Bargiggia S, Maconi G, et al 132,of over three hundred 
and eleven patients with CD and 200 patients with UC , hepatobiliary 
abnormalities were found at Ultrasound  in 54.2% and 55.9% of CD and 
UC  patients,  respectively.  Liver  enlargement  and  mild-to-moderate  to 
severe liver steatosis were found in 25.7% and 39.5% of CD patients and 
in  25.5% and  35.5% of  UC patients,  respectively.  The  prevalence  of 
gallstones  among  CD  patients  was  11%,  higher  than  that  among  UC 
patients (7.5%). 
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POLYARTRALGIA AND PAUCIARTHRALGIA 
In a  study by  Orchard TR,  et  al112,  976 patients  with ulcerative 
colitis  and 483 patients  with  Crohn's  disease   were  reviewed.  Type 1 
arthralgia  occurred in 3.6% of patients with UC and in 6.0% of those 
with CD.
Type 2 occurred in 2.5% of patients with UC and 4.0% of those 
with CD .
Brynskov J, Binder V.et al 133reported  mild arthritis/arthralgias  as 
the  most  frequent  extraintestinal  manifestation  in  inflammatory  bowel 
disease (IBD) and  to occur in 10-35% of patients.
D'Incà  R,  Podswiadek  M,  et  al134  in  a  cohort  of  651  patients 
reported  that arthropathy was axial in 52%, oligoarticular in 16% and 
polyarticular in 23%.
In our study the percentage of pauciarthralgia and polyarthralgia 
are 25.6% and 7.69 % respectively.
LOW BACK ACHE 
Axial  arthropathy  manifesting  as  sacroiliitis  or  low backache  is 
reported in 25.6% in our study.
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        Sleisenger says isolated sacroiliitis occurs in 10-15% of cases of 
UC  and  bilateral  symmetrical  sacroiliitis  without  progression  to 
spondylitis occurs in 4-18% of CD 
ERYTHEMA NODOSUM
Our  study  has one case  of erythema nodosum. Prevalence  of EN 
in  our  study  is   2.6% .  EN was  diagnosed  in  a  female  patient  with 
Crohn’s disease in our study.
In a study by  Farhi D,et al135among 2402 patients  with Crohn 
disease (63.3%) and  ulcerative colitis (31.0%), 5.8% had at least 1 skin 
manifestation. The most frequent dermatologic symptom was erythema 
nodosum (4.0%). Erythema nodosum was significantly and independently 
associated with a diagnosis of Crohn’s disease and  female sex .  
Yüksel I,et al136 , out of 352 patients studied, 9.3%  had  at least 1 
major cutaneous manifestation. The prevalence of EN in IBD was 7.4%. 
Erythema  nodosum  was  more  common  in  Crohn's   disease   than  in 
ulcerative colitis. 
In  a  study by  Moravvej  H et  al137,  the prevalence  of  cutaneous 
manifestations  in  ulcerative  colitis   was  4.07%,  and more  frequent  in 
females  (52%)  than  in  males  (48%)  .  Also,  Erythema  nodosum  was 
diagnosed only  in female patients with Crohn's disease in that study . 
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PYODERMA GANGRENOSUM        
         Yüksel I,et al136, studied 352 patients and 34 patients (9.3%), who 
presented with at least 1 major cutaneous manifestation. The prevalence 
of   Pyoderma  gangrenosum  in  their  study  was   2.3%.In  a  study  by 
Moravvej  H,et  al137,  the  prevalence  of  cutaneous  manifestations  was 
5.9%. These manifestations were higher in Crohn's disease (7.29%) than 
in  ulcerative  colitis  (4.07%),  more  frequent  in  females  (52%)  than  in 
males  (48%)  and   pyoderma  gangrenosum  was  seen  more  often  in 
ulcerative colitis. 
         In our study the frequency of  PG is 2.56%and  is associated with  
UC. The percentage of UC patients  with PG is 2.7%.
APHTHOUS ULCER               
          Aphthous ulcer is present in 5.12% of patients in our study. 
Sleisenger   says aphthous  ulcers  of  the  mouth are  common  among 
patients with Crohn's disease and ulcerative colitis but are also frequently 
seen among otherwise healthy persons. At least 10% of patients with UC 
develop oral aphthous ulcers. These lesions usually occur with flares of 
colitis and resolve on control of the bowel disease.
61
ANGULAR STOMATITIS             
           It is present in 15.38% of patients examined in our study.Out of the 
2  cases  of  CD,  angular  stomatitis   is  found  in  one  case.    Angular 
stomatitis   is  seen  in  nearly  8%  of  patients  with  Crohn's  disease 
according to Sleisenger . 
           In a study by  Moravvej H et al138, the prevalence of cutaneous 
manifestations in ulcerative colitis  was 4.07% , and was more frequent in 
females (52%) than in males (48%). Aphthous stomatitis was observed 
more frequently in Crohn's disease. 
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                                         CONCLUSION
1. Ulcerative colitis is more prevalent than Crohn’s Disease in our 
study.
2.  Sex ratio of Inflammatory Bowel Disease, M:F = 1:2.5
3. The peak age group affected by IBD   is 31-40yrs.
4. Total colitis is the predominant colonoscopic finding in our study.
5. The majority of   Ulcerative colitis cases are having   severe 
disease  (81.1%)  based on Truelove & Witts criteria.
6.  Extraintestinal manifestations  of IBD in our study is  64 %. 
(25patients)
7. The most common extraintestinal manifestations   are 
Pauciarthralgia (25.6%)  & Fatty liver (23.1%) 
8. No cases of Primary Sclerosing Cholangitis and eye manifestations 
like uveitis are found in our study 
9. The extraintestinal manifestations  in our study are comparable to 
published literature worldwide.
 
.
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                              SUMMARY
          
The  study  “EXTRA  INTESTINAL  MANIFESTATIONS  OF 
INFLAMMATORY BOWEL DISEASE ”  is   a  cross  sectional   study 
conducted  on   patients  visiting  the  outpatient  Department  of 
Gastroenterology ,Government Rajaji Hospital , Madurai. 
Our  aim was  to  study   the  clinical  presentation  of  IBD in  our 
hospital and the extraintestinal manifestations of the disease. All cases of 
bleeding  PR  who  satisfied  the  clinical,  colonoscopic  and  histologic 
criteria of IBD were included as well as cases of proven IBD.
Thirty  nine   patients  with  inflammatory  bowel  disease   were 
included in the study. Colonoscopic examination  of these patients were 
done after taking proper consent. Extent of the disease was determined by 
colonoscopy.  Biopsy  specimens  were  taken  and  sent   for 
histopathological  examination.  Severity  of  disease  was  assessed  by 
Truelove  &  Witts  criteria.  Selected  patients  underwent  clinical  and 
laboratory evaluation to detect the extraintestinal manifestations.
The  information  collected  regarding  all  the  selected  cases  were 
recorded in  a  Master  Chart  and   data  analysis  done with  the  help  of 
Epidemiological Information Package (EPI 2008).
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Analysis  of  data  shows that  Ulcerative colitis  is  more prevalent 
than Crohn’s disease in our study and that IBD manifestations are seen 
predominantly in females.  The age group with maximum prevalence of 
disease in our  study is  31-40 years .Total  colitis  is  the most  common 
colonoscopic finding seen.  Of the 39 patients, 25 patients  have at least 
one  extraintestinal   feature,  which  accounts  to   64%  in  our  study. 
Pauciarticular arthralgias and Fatty liver are the most frequently found 
extraintestinal manifestations.  
Our  study  had  only  39  patients  and  a  larger  patient  population 
could throw more light on the extraintestinal manifestations.  
65
BIBLIOGRAPHY
1. Kirsner JB: Historical aspects of inflammatory bowel disease.  J Clin 
Gastroenterol  1988; 10:286.
2. Dalziel TK: Thomas Kennedy Dalziel 1861-1924. Chronic interstitial 
enteritis.  Dis Colon Rectum  1989; 32:1076.
3. Baron JH: Inflammatory bowel disease up to 1932.  Mt Sinai J  
Med  2000; 67:174.
4. Crohn BB, Ginzburg L, Oppenheimer GD: Regional ileitis, a 
pathological and clinical entity.  JAMA  1932; 99:1323
. 
5. Wilks S: Lectures on Pathological Anatomy,  London, Ongman, 
Brown, Green, Longman, & Roberts, 1859.
 
6. Wilks S: Morbid appearances in the intestines of Miss Bankes.  Med 
Times Gazette  1859;264.
7. Hawkins HP: An address on the natural history of ulcerative colitis and 
its bearing on treatment.  BMJ  1909; 765:
 
8. Loftus Jr EV, Schoenfeld P, Sandborn WJ: The epidemiology and 
natural history of Crohn's disease in population-based patient cohorts 
from North America: A systematic review.  Aliment Pharmacol  
Ther  2002; 16:51. 
9. Loftus Jr EV, Silverstein MD, Sandborn WJ, et al: Crohn's disease in 
Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and 
survival.  Gastroenterology  1998; 114:1161.
 
10. Munkholm P: Crohn's disease—occurrence, course and prognosis: An 
epidemiologic cohort-study.  Dan Med Bull  1997; 44:287.
.
11. Andres PG, Friedman LS: Epidemiology and the natural course of 
inflammatory bowel disease.  Gastroenterol Clin North 
Am  1999; 28:2555. 
12.Loftus Jr EV: Clinical epidemiology of inflammatory bowel disease: 
Incidence, prevalence, and environmental influences. 
 Gastroenterology  2004; 126:1504. 
66
13. Probert CS, Jayanthi V, Rampton DS, et al: Epidemiology of 
inflammatory bowel disease in different ethnic and religious groups: 
Limitations and aetiological clues.  Int J Colorectal Dis  1996; 11:25.
14. Probert CS, Jayanthi V, Pinder D, et al: Epidemiological study of 
ulcerative proctocolitis in Indian migrants and the indigenous population 
of Leicestershire.  Gut  1992; 33:687. 
15. Carr I, Mayberry JF: The effects of migration on ulcerative colitis: A 
three-year prospective study among Europeans and first- and second- 
generation South Asians in Leicester (1991-1994).  Am J 
Gastroenterol  1999; 94:2918. 
16. MacDonald TT: Effector and regulatory lymphoid cells and cytokines 
in mucosal sites.  Curr Top Microbiol Immunol  1999; 236:113. 
17. Fuss IJ, Heller F, Boirivant M, et al: Nonclassical CD1d-restricted 
NK T cells that produce IL-13 characterize an atypical Th2 response in 
ulcerative colitis.  J Clin Invest  2004; 113:1490. 
18 Lopez-Cubero SO, Sullivan KM, McDonald GB: Course of Crohn's 
disease after allogeneic marrow transplantation. 
 Gastroenterology  1998; 114:433.
19. Sustento-Reodica N, Ruiz P, Rogers A, et al: Recurrent Crohn's 
disease in transplanted bowel.  Lancet  1997; 349:688. 
20. Sturm A, Fiocchi C: Life and death in the gut: More killing, less 
Crohn's.  Gut  2002; 50:148.
 21. Kett K, Rognum TO, Brandtzaeg P: Mucosal subclass distribution of 
immunoglobulin G-producing cells is different in ulcerative colitis and 
Crohn's disease of the colon.  Gastroenterology  1987; 93:919.
22. Scott MG, Nahm MH, Macke K, et al: Spontaneous secretion of IgG 
subclasses by intestinal mononuclear cells: Differences between 
ulcerative colitis, Crohn's disease, and controls.  Clin Exp 
Immunol  1986; 66:209.
23. Snook JA, de Silva HJ, Jewell DP: The association of auto-immune 
disorders with inflammatory bowel disease.  Q J Med  1989; 72:835.
67
24. Aronson RA, Cook SL, Roche JK: Sensitization to epithelial antigens 
in chronic mucosal inflammatory disease: I. Purification, characterization, 
and immune reactivity of murine epithelial cell-associated components 
(ECAC).  J Immunol  1983; 131:2796.
25. Das KM, Dasgupta A, Mandal A, et al: Autoimmunity to cytoskeletal 
protein tropomyosin: A clue to the pathogenetic mechanism for ulcerative 
colitis.  J Immunol  1993; 150:2487.
26. Bhagat S, Das KM: A shared and unique peptide in the human colon, 
eye, and joint detected by a monoclonal antibody. 
 Gastroenterology  1994; 107:103.
27. Das KM, Vecchi M, Sakamaki S: A shared and unique epitope(s) on 
human colon, skin, and biliary epithelium detected by a monoclonal 
antibody.  Gastroenterology  1990; 98:464.
28. Saxon A, Shanahan F, Landers C, et al: A distinct subset of 
antineutrophil cytoplasmic antibodies is associated with inflammatory 
bowel disease.  J Allergy Clin Immunol  1990; 86:202.
29. Seibold F, Slametschka D, Gregor M, et al: Neutrophil 
autoantibodies: A genetic marker in primary sclerosing cholangitis and 
ulcerative colitis.  Gastroenterology  1994; 107:532.
30. Shanahan F: Neutrophil autoantibodies in inflammatory bowel 
disease: Are they important?.  Gastroenterology  1994; 107:586.
31. Terjung B, Spengler U, Sauerbruch T, et al: “Atypical p-ANCA” in 
IBD and hepatobiliary disorders react with a 50-kilodalton nuclear 
envelope protein of neutrophils and myeloid cell lines. 
 Gastroenterology  2000; 119:310.
32. Vecchi M, Bianchi MB, Sinico RA, et al: Antibodies to neutrophil 
cytoplasm in Italian patients with ulcerative colitis: Sensitivity, 
specificity, and recognition of putative antigens.  Digestion  1994; 55:34.
33. Sandborn WJ, Landers CJ, Tremaine WJ, et al: Antineutrophil 
cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-
anal anastomosis.  Am J Gastroenterol  1995; 90:740.
34. Hamann A, Andrew DP, Jablonski-Westrich D, et al: Role of alpha 4-
integrins in lymphocyte homing to mucosal tissues in vivo.  J 
Immunol  1994; 152:3282.
68
35. Senju M, Wu KC, Mahida YR, et al: Two-color immunofluorescence 
and flow cytometric analysis of lamina propria lymphocyte subsets in 
ulcerative colitis and Crohn's disease.  Dig Dis Sci  1991; 36:1453.
36. Gibson PR, van de Pol E, Pullman W, Doe WF: Lysis of colonic 
epithelial cells by allogeneic mononuclear and lymphokine activated 
killer cells derived from peripheral blood and intestinal mucosa: Evidence 
against a pathogenic role in inflammatory bowel disease. 
 Gut  1988; 29:1076.
37. Dalton HR, Hoang P, Jewell DP: Antigen induced suppression in 
peripheral blood and lamina propria mononuclear cells in inflammatory 
bowel disease.  Gut  1992; 33:324.
38. Trejdosiewicz LK, Smart CJ, Oakes DJ, et al: Expression of T-cell 
receptors TcR1 (gamma/delta) and TcR2 (alpha/beta) in the human 
intestinal mucosa.  Immunology  1989; 68:7.
39. Raedler A, Fraenkel S, Klose G, et al: Elevated numbers of peripheral 
T cells in inflammatory bowel diseases displaying T9 antigen and Fc 
alpha receptors.  Clin Exp Immunol  1985; 60:518.
40. Duchmann R, Strober W, Alling DW, et al: T-cell receptor Vβ gene 
expression in inflammatory bowel disease lamina propria lymphocytes: 
Evidence for altered Vβ gene usage.  Inflamm Bowel Dis  1995; 1:184.
41. Meuret G, Bitzi A, Hammer B: Macrophage turnover in Crohn's 
disease and ulcerative colitis.  Gastroenterology  1978; 74:501. 
42. Powrie F, Coffman RL: Cytokine regulation of T-cell function: 
Potential for therapeutic intervention.  Immunol Today  1993; 14:270.
43. Smith KM, Eaton AD, Finlayson LM, et al: Oral tolerance.  Am J 
Respir Crit Care Med  2000; 162:S175. 
44. Mayer L, Shlien R: Evidence for function of Ia molecules on gut 
epithelial cells in man.  J Exp Med  1987; 166:1471
45. Boughton-Smith N, Pettipher R: Lipid mediators and cytokines in 
inflammatory bowel disease.  Eur J Gastroenterol Hepatol  1990; 2:241. 
46. Binder V: Genetic epidemiology in inflammatory bowel disease.  Dig 
Dis  1998; 16:351. 
69
47. Ogura Y, Bonen DK, Inohara N, et al: A frameshift mutation in NOD2 
associated with susceptibility to Crohn's disease.  Nature  2001; 411:603.
48. Hugot JP, Chamaillard M, Zouali H, et al: Association of NOD2 
leucine-rich repeat variants with susceptibility to Crohn's disease. 
 Nature  2001; 411:599.
49 Cuthbert AP, Fisher SA, Mirza MM, et al: The contribution of NOD2 
gene mutations to the risk and site of disease in inflammatory bowel 
disease.  Gastroenterology  2002; 122:867.
50. Hampe J, Grebe J, Nikolaus S, et al: Association of NOD2 (CARD 
15) genotype with clinical course of Crohn's disease: A cohort study. 
 Lancet  2002; 359:1661.
51. Lesage S, Zouali H, Cezard JP, et al: CARD15/NOD2 mutational 
analysis and genotype-phenotype correlation in 612 patients with 
inflammatory bowel disease.  Am J Hum Genet  2002; 70:845.
52 Abreu MT, Taylor KD, Lin YC, et al: Mutations in NOD2 are 
associated with fibrostenosing disease in patients with Crohn's disease. 
 Gastroenterology  2002; 123:679.
 53. Satsangi J, Jewell DP, Rosenberg WM, et al: Genetics of 
inflammatory bowel disease.  Gut  1994; 35:696. 
54. Orholm M, Binder V, Sorensen TI, et al: Concordance of 
inflammatory bowel disease among Danish twins: Results of a 
nationwide study.  Scand J Gastroenterol  2000; 35:1075.
55. Thompson NP, Driscoll R, Pounder RE, et al: Genetics versus 
environment in inflammatory bowel disease: Results of a British twin 
study.  BMJ  1996; 312:95.
56. Tysk C, Lindberg E, Jarnerot G, et al: Ulcerative colitis and Crohn's 
disease in an unselected population of monozygotic and dizygotic twins: 
A study of heritability and the influence of smoking.  Gut  1988; 29:990
57. Satsangi J, Parkes M, Louis E, et al: Two-stage genome-wide search 
in inflammatory bowel disease provides evidence for susceptibility loci 
on chromosomes 3, 7, and 12.  Nat Genet  1996; 14:199.
70
58. van Heel DA, Satsangi J, Carey AH, et al: Inflammatory bowel 
disease: Progress toward a gene.  Can J Gastroenterol  2000; 14:207.
59. Parkes M, Barmada MM, Satsangi J, et al: The IBD2 locus shows 
linkage heterogeneity between ulcerative colitis and Crohn disease.  Am J 
Hum Genet  2000; 67:1605.
 60. Schwab M, Schaeffeler E, Marx C, et al: Association between the 
C3435T MDR1 gene polymorphism and susceptibility for ulcerative 
colitis.  Gastroenterology  2003; 124:26. 
61. Sonnenberg A: Occupational distribution of inflammatory bowel 
disease among German employees.  Gut  1990; 31:1037
62. Chadwick VS, Anderson RP: Inflammatory products of commensal 
bacteria and gastrointestinal disorders.  Dig Dis  1990; 8:253. 
63. Duchmann R, Kaiser I, Hermann E, et al: Tolerance exists towards 
resident intestinal flora but is broken in active inflammatory bowel 
disease (IBD).  Clin Exp Immunol  1995; 102:448.
64. Duchmann R, Schmitt E, Knolle P, et al: Tolerance toward resident 
intestinal flora in mice is abrogated in experimental colitis and restored 
by treatment with interleukin-10 or antibodies to interleukin-12.  Eur J 
Immunol  1996; 26:934.
.65. Boyko EJ, Perera DR, Koepsell TD, et al: Effects of cigarette 
smoking on the clinical course of ulcerative colitis.  Scand J  
Gastroenterol  1988; 23:1147.
.66. Merrett MN, Mortensen N, Kettlewell M, et al: Smoking may 
prevent pouchitis in patients with restorative proctocolectomy for 
ulcerative colitis.  Gut  1996; 38:362. 
67. Corrao G, Tragnone A, Caprilli R, et al: Risk of inflammatory bowel 
disease attributable to smoking, oral contraception and breastfeeding in 
Italy: A nationwide case-control study. Cooperative Investigators of the 
Italian Group for the Study of the Colon and the Rectum (GISC).  Int J 
Epidemiol  1998; 27:397.
 
68. Rutgeerts P, D'Haens G, Hiele M, et al: Appendectomy protects 
against ulcerative colitis.  Gastroenterology  1994; 106:1251.
71
69. Smithson JE, Radford-Smith G, Jewell GP: Appendectomy and 
tonsillectomy in patients with inflammatory bowel disease.  J Clin 
Gastroenterol  1995; 21:283. 97. 
70.Langholz E, Munkholm P, Davidsen M, et al: Course of ulcerative 
colitis: Analysis of changes in disease activity over years. 
 Gastroenterology  1994; 107:3. 
71. D'Haens G, Geboes K, Peeters M, et al: Patchy cecal inflammation 
associated with distal ulcerative colitis: A prospective endoscopic study. 
 Am J Gastroenterol  1997; 92:1275103.
72 Belaiche J, Louis E, D'Haens G, et al: Acute lower gastrointestinal 
bleeding in Crohn's disease: Characteristics of a unique series of 34 
patients. Belgian IBD Research Group.  Am J 
Gastroenterol  1999; 94:2177. 
73 Greenstein AJ, Lachman P, Sachar DB, et al: Perforating and non-
perforating indications for repeated operations in Crohn's disease: 
Evidence for two clinical forms.  Gut  1988; 29:588. 
74. Dvorak AM, Silen W: Differentiation between Crohn's disease and 
other inflammatory conditions by electron microscopy.  Ann 
Surg  1985; 201:53
75. Both H, Torp-Pedersen K, Kreiner S, et al: Clinical appearance at 
diagnosis of ulcerative colitis and Crohn's disease in a regional patient 
group.  Scand J Gastroenterol  1983; 18:987.
76. Pimentel M, Chang M, Chow EJ, et al: Identification of a prodromal 
period in Crohn's disease but not ulcerative colitis.  Am J 
Gastroenterol  2000; 95:3458.
77. Rao SS, Holdsworth CD, Read NW: Symptoms and stool patterns in 
patients with ulcerative colitis.  Gut  1988; 29:342. 
78. Scotiniotis I, Rubesin SE, Ginsberg GG: Imaging modalities in 
inflammatory bowel disease.  Gastroenterol Clin North Am  1999; 28:391
79 Veloso FT, Carvalho J, Magro F: Immune-related systemic 
manifestations of inflammatory bowel disease: A prospective study of 
792 patients.  J Clin Gastroenterol  1996; 23:29..
72
80. Lapidus A, Bangstad M, Astrom M, Muhrbeck O: The prevalence of 
gallstone disease in a defined cohort of patients with Crohn's disease.  Am 
J Gastroenterol  1999; 94:1261.
81. Danzi JT: Extraintestinal manifestations of idiopathic inflammatory 
bowel disease.  Arch Intern Med  1988; 148:297.
82. Farmer RG, Hawk WA, Turnbull Jr RB: Clinical patterns in Crohn's 
disease: A statistical study of 615 cases.  Gastroenterology  1975; 68:627.
83. Salmi M, Jalkanen S: Endothelial ligands and homing of mucosal 
leukocytes in extraintestinal manifestations of IBD.  Inflamm Bowel  
Dis  1998; 4:149.
84. Orchard TR, Wordsworth BP, Jewell DP: Peripheral arthropathies in 
inflammatory bowel disease: Their articular distribution and natural 
history.  Gut  1998; 42:387.
85. Orchard TR, Thiyagaraja S, Welsh KI, et al: Clinical phenotype is 
related to HLA genotype in the peripheral arthro-pathies of inflammatory 
bowel disease.  Gastroenterology  2000; 118:274.
86. Gravallese EM, Kantrowitz FG: Arthritic manifestations of 
inflammatory bowel disease.  Am J Gastroenterol  1988; 83:703.
87. Orchard TR, Jewell DP: The importance of ileocaecal integrity in the 
arthritic complications of Crohn's disease.  Inflamm Bowel  
Dis  1999; 5:92.
88. Scott Jr WW, Fishman EK, Kuhlman JE, et al: Computed tomography 
evaluation of the sacroiliac joints in Crohn disease: Radiologic/clinical 
correlation.  Skeletal Radiol  1990; 19:207.
89. Wakefield AJ, Sankey EA, Dhillon AP, et al: Granulomatous 
vasculitis in Crohn's disease.  Gastroenterology  1991; 100:1279.
90 Freeman HJ, Freeman KJ: Prevalence rates and an evaluation of 
reported risk factors for osteonecrosis (avascular necrosis) in Crohn's 
disease.  Can J Gastroenterol  2000; 14:138.
91. Bousvaros A, Marcon M, Treem W, et al: Chronic recurrent 
multifocal osteomyelitis associated with chronic inflammatory bowel 
disease in children.  Dig Dis Sci  1999; 44:2500.
73
92. Lebwohl M, Lebwohl O: Cutaneous manifestations of inflammatory 
bowel disease.  Inflamm Bowel Dis  1998; 4:142.
93. Finkel SI, Janowitz HD: Trauma and the pyoderma gangrenosum of 
inflammatory bowel disease.  Gut  1981; 22:410.
94. Lisciandrano D, Ranzi T, Carrassi A, et al: Prevalence of oral lesions 
in inflammatory bowel disease.  Am J Gastroenterol  1996; 91:7.
95. Hackzell-Bradley M, Hedblad MA, Stephansson EA: Metastatic 
Crohn's disease: Report of three cases with special reference to 
histopathologic findings.  Arch Dermatol  1996; 132:928.
96. Zlatanic J, Fleisher M, Sasson M, et al: Crohn's disease and acute 
leukocytoclastic vasculitis of skin.  Am J Gastroenterol  1996; 91:2410.
97. Travis S, Innes N, Davies MG, et al: Sweet's syndrome: An unusual 
cutaneous feature of Crohn's disease or ulcerative colitis. The South West 
Gastroenterology Group.  Eur J Gastroenterol Hepatol  1997; 9:715.
98. Lee FI, Bellary SV, Francis C: Increased occurrence of psoriasis in 
patients with Crohn's disease and their relatives.  Am J 
Gastroenterol  1990; 85:962.
99 Hopkins DJ, Horan E, Burton IL, et al: Ocular disorders in a series of 
332 patients with Crohn's disease.  Br J Ophthalmol  1974; 58:732.
100. Lyons JL, Rosenbaum JT: Uveitis associated with inflammatory 
bowel disease compared with uveitis associated with 
spondyloarthropathy.  Arch Ophthalmol  1997; 115:61.
101. Rasmussen HH, Fallingborg JF, Mortensen PB, et al: Hepatobiliary 
dysfunction and primary sclerosing cholangitis in patients with Crohn's 
disease.  Scand J Gastroenterol  1997; 32:604.
102. Over HH, Ulgen S, Tuglular T, et al: Thrombophilia and 
inflammatory bowel disease: Does factor V mutation have a role?.  Eur J 
Gastroenterol Hepatol  1998; 10:827.
103. Zauber NP, Sabbath-Solitare M, Rajoria G, Mogan G: Factor V 
Leiden mutation is not increased in patients with inflammatory bowel 
disease.  J Clin Gastroenterol  1998; 27:215.
74
104. Mahmud N, Molloy A, McPartlin J, et al: Increased prevalence of 
methylenetetrahydrofolate reductase C677T variant in patients with 
inflammatory bowel disease, and its clinical implications. 
 Gut  1999; 45:389.
105. Solem CA, Loftus EV, Tremaine WJ, et al: Venous 
thromboembolism in inflammatory bowel disease.  Am J 
Gastroenterol  2004; 99:97.
106. Fireman Z, Osipov A, Kivity S, et al: The use of induced sputum in 
the assessment of pulmonary involvement in Crohn's disease.  Am J 
Gastroenterol  2000; 95:730.
107. Elsehety A, Bertorini TE: Neurologic and neuropsychiatric 
complications of Crohn's disease.  South Med J  1997; 90:606.
108. Levine JB: Extraintestinal manifestations of inflammatory bowel  
disease.   In: Kirsner JB, ed. Inflammatory Bowel Disease, 
 Philadelphia: WB Saunders; 2000:397.
109. Weber P, Seibold F, Jenss H: Acute pancreatitis in Crohn's disease. 
 J Clin Gastroenterol  1993; 17:286.
 
110. Barthet M, Hastier P, Bernard JP, et al: Chronic pancreatitis and 
inflammatory bowel disease: True or coincidental association?.  Am J 
Gastroenterol  1999; 94:2141.
111. Hegnhoj J, Hansen CP, Rannem T, et al: Pancreatic function in 
Crohn's disease.  Gut  1990; 31:1076. 
112. Orchard TR, Wordsworth BP, Jewell DP: Peripheral arthropathies in 
inflammatory bowel disease: Their articular distribution and natural 
history.  Gut  1998; 42:387.
113. Miehsler W, Reinisch W, Valic E, et al: Is inflammatory bowel 
disease an independent and disease-specific risk factor for 
thromboembolism?.  Gut  2004; 53:542.
114. Talbot RW, Heppell J, Dozois RR, et al: Vascular complications of 
inflammatory bowel disease.  Mayo Clin Proc  1986; 61:140.
115. Schapira M, Henrion J, Ravoet C, et al: Thromboembolism in 
inflammatory bowel disease.  Acta Gastroenterol Belg  1999; 62:182.
75
116. Liebman HA, Kashani N, Sutherland D, et al: The factor V Leiden 
mutation increases the risk of venous thrombosis in patients with 
inflammatory bowel disease.  Gastroenterology  1998; 115:830.
117. Papa A, Danese S, Grillo A, et al: Review article: Inherited 
thrombophilia in inflammatory bowel disease.  Am J 
Gastroenterol  2003; 98:1247.
118. Guedon C, Cam-Duchez V, Lalaude O, et al: Prothrombotic inherited 
abnormalities other than factor V Leiden mutation do not play a role in 
venous thrombosis in inflammatory bowel disease.  Am J 
Gastroenterol  2001; 96:1448.
119 Greenstein AJ, Sachar DB, Panday AK, et al: Amyloidosis and 
inflammatory bowel disease: A 50-year experience with 25 patients. 
 Medicine (Baltimore)  1992; 71:261
.
120. Patwardhan RV, Heilpern RJ, Brewster AC, et al: Pleuropericarditis
—an extraintestinal complication of inflammatory bowel disease: Report 
of three cases and review of literature.  Arch Intern Med  1983; 143:94.
121. Rheingold OJ: Inflammatory bowel disease and pericarditis [Letter]. 
 Ann Intern Med  1975; 82:592.
122. Mukhopadhyay D, Nasr K, Grossman BJ, et al: Pericarditis 
associated with inflammatory bowel disease.  JAMA  1970; 211:1540.
123. Oxentenko AS, Loftus EV, Oh JK, et al: Constrictive pericarditis in 
chronic ulcerative colitis.  J Clin Gastroenterol  2002; 34:247.
124. Gujral N, Friedenberg F, Friedenberg J, et al: Pleuropericarditis 
related to the use of mesalamine.  Dig Dis Sci  1996; 41:624.
125 Ishikawa N, Imamura T, Nakajima K, et al: Acute pericarditis 
associated with 5-aminosalicylic acid (5-ASA) treatment for severe active 
ulcerative colitis.  Intern Med  2001; 40:901.
126. Godet PG, Cowie R, Woodman RC, et al: Pulmonary function 
abnormalities in patients with ulcerative colitis.  Am J 
Gastroenterol  1997; 92:1154.
76
127. McKee AL, Rajapaksa A, Kalish PE, et al: Severe interstitial 
pulmonary fibrosis in a patient with chronic ulcerative colitis.  Am J 
Gastroenterol  1983; 78:86.
128. Forrest JA, Shearman DJ: Pulmonary vasculitis and ulcerative 
colitis.  Am J Dig Dis  1975; 20:482.
129. Mahadeva R, Walsh G, Flower CD, et al: Clinical and radiologic 
characteristics of lung disease in inflammatory bowel disease.  Eur 
Respir J  2000; 15:4.
130 Navaneethan U, Remzi FH, Nutter B, Fazio VW, Shen B. Am J 
Gastroenterol. 2009 Jun 23. 
131. Kurchin A, Ray JE, Bluth EI, Merritt CR, Gathright JB Jr, Pehrsson 
BF, Ferrari BT. Dis Colon Rectum. 1984 Sep;27(9):585-8. 
132.Bargiggia S, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, 
Todaro I, Greco S, Manzionna G, Bianchi Porro G. J Clin Gastroenterol. 
2003 May-Jun;36(5):417-20.
 133. Brynskov J, Binder V. Eur J Gastroenterol Hepatol. 1999 
Sep;11(9):1001-5. 
 134.D'Incà R, Podswiadek M, Ferronato A, Punzi L, Salvagnini M, 
Sturniolo GC. Dig Liver Dis.  2009 Aug;41(8):565-9. Epub 2009 Mar 10
135. Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, 
Aractingi S, Khosrotehrani K. Medicine (Baltimore). 2008 
Sep;87(5):281-93.
 136.Yüksel I, Başar O, Ataseven H, Ertuğrul I, Arhan M, Ibiş M, Dağli 
U, Demirel BT, Ulker A, Seçilmiş S, Saşmaz N. Inflamm Bowel Dis. 
2009 Apr;15(4):546-50. 
137.Moravvej H, Razavi GM, Farshchian M, Malekzadeh R. Indian J 
Dermatol Venereol Leprol. 2008 Nov-Dec;74(6):607
138.Harrison`s text ok of Internal Medicine 17 th Edition
139.Sleisenger & Fordtran`s Textbook of Gastroenterology.
77
GLOSSARY
           IBD             -INFLAMMATORY BOWEL DISEASE
CD               -CROHNS DISEASE 
  
UC               -ULCERATIVE COLITIS
FL                -FATTY  LIVER
GS               -GALL STONES
EN               -ERYTHEMA NODOSUM
PG               -PYODERMA GANGRENOSUM
L                  -LOW BACK ACHE
AU               -APHTHOUS ULCER
AS               -ANGULAR STOMATITIS
P                  -PAUCIARTICULAR ARTHROPATHY
Py                -POLYARTICULAR ARTHROPATHY  
N                 -NORMAL
SF               -SPLENIC FLEXURE
DPS            -DISTAL PROCRO SIGMOIDITIS
DP              -DISTAL PROCTITIS
TC              -TOTAL COLITIS
TIC            -TERMINAL ILEUM & COLON 
S                -SEVERE DISEASE    ,        M        - MILD DISEASE
I                -INTERMEDIATE DISEASE
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PROFILE OF IBD AND EXTRAINTESTINAL 
MANIFESTATION
NAME                                             AGE                    SEX
ADDRESS                                        IP No 
OCCUPATION
SYMPTOMS                       ULCERATIVE COLITIS 
CROHNS
WITH DURATION             Rectal bleeding                       Diarrhoea
                                            Diarrhoea                                 Abd. Pain
                                            Abd. pain                                  weight 
loss/malnutrition 
                                            Anorexia/nausea                   Anorexia/nausea
                                            Fever                                         Fever
                                                                                               Anaemia
PAST H/O
                                   h/o HT/ DM /PTB /IHD /Stroke
                                   h/o Sx (ileocaecal)
                                   h/o malignancy
                                    h/o appendectomy
PERSONEL H/O        Smoking – duration
                                    Alcohol / pan chewing
                                    STD
FAMILY H/O           H/o malignancy / similar illness
DRUG H/O               Previous treatment / steroids
O/E
       PR                     BP                      RR                   Ht                      Wt
       Pallor 
       Clubbing
       Cyanosis
       Pedal edema
       Gen. Lymphadenopathy
1  P/A
        Penile /vulvar d/s
      Anal fissure / fistula /perirectal abcess
      Per rectal examination
2  CVS
      Cardiomyopathy
      Myo / endocarditis
      Pleura pericarditis
79
3 Resp. 
4  CNS
5 Ocular
                 Episceritis 
                 Scleritis
                 Uveitis
                Keratopathy
                Nt blindness
Musculoskeletal :       clubbing
                                       Arthritis  pauci   / poly
                                       Low backache
                                       Axial arthropathy
                                       Septic joint
                                       Osteopenia /osteoporosis
Muco cutaneous
                                    Pyoderma gangrenosom
                                    Erythema nodosum
                                    Apthous ulcer
                                    Angular chelitis
                                    Cutaneous PAN
                                    Leucocytoclastic vasculitis
                                    Psoriasis
                                    Epidermolysis bullosa congenita
INVESTIGATIONS
     Hb                   TC                          DC                        ESR 
CRP
    Hct                    Plt                         Fibrinogen
    LFT                                              EYE slit lamp examination      Rt 
Lt   
                                                                      Ant chamber
   Amylase                                                   Post chamber
   USG        Fatty liver
                   Gall stones
OGD
Colonoscopy / sigmoidoscopy
Biopsy 
      CDAI                                                                UCDAI
    Liquid/very soft stools                               stool freq
    Abd. Pain                                                      rectal bleeding
    Gen well being                                            Mucosal appearance
    EI disease                                                     physician global assessment
    Abd  mass                            
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    HCT
    Body weight
Disease extent
     Ulcerative colitis                               Crohn’s 
     Rectum only                                      Colitis only
     Distal to splenic flexure                   Ileocolonic
     Subtotal colitis                                  Terminal ileum +caecum
     Total colitis                                         Prox small bowel only
                                                                   Ext. Small and large bowel
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